Henlius Entered into a License Agreement with Eurofarma for Three Biosimilar Products in Latin America
Shots:
- Henlius to receive a total value of ~$50.5M including a $4.5M up front. The companies collaborated to develop, manufacture, and commercialize Henlius' 3 products i.e., Hanlikang (rituximab, biosimilar), Hanquyou (trastuzumab, biosimilar) & Hanbeitai (bevacizumab biosimilar) in 16 Latin America countries
- Eurofarma to acquire exclusive rights to Hanlikang in 12 countries, Hanquyou in 11 countries, and Hanbeitai in 15 countries including Mexico. Eurofarma will also obtain semi-exclusive rights in Brazil
- This collaboration is a testament to Henlius' product quality, operational strength & continuance of Henlius’ goal of expanding its global footprint. Henlius & Farma de Colombia collaborated to promote Hanlikang's commercialization in Colombia, Peru, Ecuador & Venezuela
Ref: Henlius | Image: Henlius
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
